Moroz L.V., Paliy M.G., Tkachenko T.V.
In this study, which enrolled 144 patients with acute viral hepatitis B, we investigated the peculiarities of acute viral hepatitides accompanied with dysbiotic disturbances and the possible ways to correct the latter using an enterosorbent Enterosgel, as well as the effects of this medicinal product on immunological markers. It has been established that adding enterosorbent Enterosgel to the comprehensive treatment of such patients contributed to toxidrome suppression, prompt regression of major clinical signs of the disorder, gastrointestinal microbiocenosis normalization and improvement of immunological markers. Enterosgel can be safely used in patients due to its good tolerability profile and absence of adverse effects.
A.V. Gorelov, A.V. Bondareva
The colibacillosis are wildly spread all over the world and takes leading positions in etiological structure of acute intestinal infections in children. In our country, due to diagnostic difficulties, rate of registration of colibacillosis is low. The clinical epidemiological characteristics and issues of differentiated diagnostic of the given disease are studied insufficiently. Until nowadays, common approaches to therapy are lacking. The article presents evaluation of therapeutic activity of various methods of start therapy of colibacillosis in children. The clinical efficiency of various classes of antibacterial medications and enterosorbents are presented.
Mikulets L.V., Voloshyn О.І., Tovkach Y.V.
Remote results of a comprehensive treatment of patients with rheumatoid arthritis with comorbid intestinal disbacteriosis after additional administration of Quercetin, Bifilact extra and Enterosgel to the standard therapy were analyzed. It was found that after administration of a comprehensive therapy including the above mentioned medicines the course of the disease of patients with RA and their general condition improved, the period or remission became longer, the necessity of repeated admissions to the hospital decreased.
ln order to assess the characteristics of the medical device ENTEROSGEL, establish the method of its use and the safety for users, this report was drawn up in the form of a critical evaluation of the relevant published clinical studies conducted with ENTEROSGEL and with other at least partially comparable medical devices already placed on the European market.
Evgenii Tkachenko, Elena B. Avalueva, Ekaterina V. Skazyvaeva, Serey V. Ivanov, Igor V. Lapinskii, Anna V. Pushkina, Olga I. Medvedeva
We consider it promising to continue clinical trials of Enterosgel as a part of standard eradication therapy of H. pylori - associated diseases of the upper gastrointestinaI tract.
Evgenii I. TKACHENKO, Elena B. AVALUEVA, Ekaterina V. SKAZYVAEVA, Sergey V. IVANOV, Igor V. LAPINSKII, Anna V. PUSHKINA, Olga I. MEDVEDEVA
Clinical trials have demonstrated the safety and efflcacy of Enterosgel administered as a monotherapy to treat patients with H. pylori - associated gastroduodenitis.
T.A. RUZHENTSOVA, A.V. GORELOV, A.A. PLOSKIREVA
The paper shows the necessity of choosing an enterosorbent for acute enteric infection (AEI) in children. It presents the basic properties of polymethylsiloxane polyhydrate as one of the drugs for enterosorption.
Tkachenko E.I., Avalueva E.B., Skazyvaeva E.V., Ivanov S.V., Pushkina A.V., Lapinskii I.V.
Enterosgel has a positive effect on the clinical performance, reducing abdominal pain severity and normalizing stool frequency in D-IBS patients, thus contributing to the harmonization of quality of life.
E.I. Tkachenko, E.B. Avalueva, E.V. Skazyvaeva, S.V. Ivanov, A.V. Pushkina, I.V. Lapinskii
The study of efficiency and safeťy of application of Enterosgel administered for tfeatment of patients with diarrhea-predominant irritable bowel syndrome had demonstrated safety and efficiency of the study medication.
Evaluation according to GSRS showed significant reduction on the scales of abdominal pain, diarrhea syndrome, dyspeptic syndrome as well as on the total measure scale. Accorcling to EGG. while studying MEA, a tendency towards normalization of GIT motor-evacuation function is evident.
The term “enterosorption” has been proposed to define a method of sorption therapy based on daily oral administration of “enterosorbents”. Enterosorbents were known in the past because the tradition of eating natural clays in case of poisoning, for improvement of well-being, jugulation of diarrhea, and, possibly, for treatment of deficiency in microelements, goes back to bygone times, and as a phenomenon known as geophagia it was observed particularly in primates [6, 7]. However, Enterosgel, comparing to other sorbents has unique hydrophobic and selective sorption properties, which made it effective and safe in wide range of medical applications. Enterosgel has proven it’s safety and efficacy during 35 years of clinical studies and use in major hospitals of the Soviet Union, it is recommended in the official guidance of Ministry of Health for treatment of various diseases. Since 2008 Enterosgel is certified as a medical device class IIa and available as an OTC treatment in Europe.
Tkachenko E.I., Avalueva E.B., Skazyvaeva E.V., Ivanov S.V., Lapinskii I.V.
Enterosgel has a positive effect on the clinical performance of the disease and is effective in reducing the symptoms of intestinal dyspepsia and diarrhea in patients with Helicobacter pylori-associated gastroduodenitis.
Tkachenko E.I., Avalueva E.B., Skazyvaeva E.V., Ivanov S.V., Lapinskii I.V., Pushkina A.V.
In the following research feasibility of Enterosgel® has been studied in treatment of patients with diarrhea-dominant irritable bowel syndrome. The work presented has scientifically proven that use of Enterosgel® is effective and safe.
Study director: Head of the Department of Internal Medicine propaedeutics, MD, Professor Tkachenko E.I.
Responsible person: Professor of the Department of Internal Medicine propaedeutics, MD Avalueva E.B.
Approximately 5-10% of the adult population are the persons suffering from alcoholism or consuming alcohol regularly or in large quantities. In everyday life a small amount of alcohol reduces sense of tension, fear, loneliness, frustration, boredom, depression.
Alfredo Guarino, Shai Ashkenazi, Dominique Gendrel, Andrea Lo Vecchio, Raanan Shamir, Hania Szajewska
Gastroenteritis severity is linked to etiology, and rotavirus is themost severe infectious agent and is frequently associated with dehydration. Dehydration reflects severity and should be monitored by established score systems. Investigations are generally not needed. Oral rehydration with hypoosmolar solution is the major treatment and should start as soon as possible. Breast-feeding should not be interrupted. Regular feeding should continue with no dietary changes including milk.
Tkachenko E.I., Avalueva E.B., Skazyvaeva E.V., Ivanov S.V., Pushkina A.V., Lapinskii I.V.
Enterosgel® has a positive effect on the clinical performance, reducing abdominal pain severity and normalizing stool frequency in D-IBS patients, thus contributing to the harmonization of quality of life. Treatment regimens that can be recommended for use in patients with D-IBS: 22.5 g of the paste with the active substance polymethylsiloxane polyhydrate 3 times a day 1 hour after meal orally for 3 consecutive weeks (paste dose should be dissolved in 200 ml of cool boiled water or washed down with at least 200 ml of cool boiled water).
Extensive clinical experience on the use of an innovative intestinal adsorbent Enterosgel has been accumulated over the past 20 years. Enterosgel provides a wide range of the therapeutic effectiveness due to its ability to bind toxins, allergens and pathogens in the gastrointestinal tract and eliminate these from the body.
The results of clinical studies of using Enterosgel in gastroenterology are presented in the collection. Enterosgel has proven itself as an effective agent for the treatment of peptic ulcer disease, inflammatory bowel disease, and diseases of the liver.
Gavrysh I. M. VISNYK VDNZU «Ukrai'ns'ka medychna stomatologichna akademija»
Patients with liver cirrhosis and comorbid intestinal dysbiosis show significant changes in biochemical parameters as improving MMP on the background of nucleotide - peptide index reduction in serum, indicating the presence of SEI in the studied patients. The combined treatment of patients with liver cirrhosis and intestinal dysbiosis by medication of «LB» and «MAH» leads to the normalization of these indicators by SEI eliminating.
Extensive clinical experience on the use of the innovative intestinal adsorbent Enterosgel has been accumulated over the past 20 years. Enterosgel provides a wide range of the therapeutic effectiveness due to its ability to bind toxins, harmful substances, pathogens and allergens in the gastrointestinal tract and eliminate these from the body. This collection of research papers presents study results of the application of Enterosgel in allergology, immunology and dermatology. Enterosgel was shown to be an effective treatment for asthma, dermal-respiratory syndrome, food allergy, urticaria, atopic dermatitis, acne vulgaris.
M. Plescik-Lech, R. Shamir, A. Guarino, H. Szajewska
Convincing evidence has accumulated showing that ondansetron reduces the risk for vomiting; however, a clearance on safety in children is needed. New evidence has reconfirmed that in Europe, where zinc deficiency is rare, there is no benefit from the use of zinc. New data, although mainly from outside of Europe, have reconfirmed that either smectite or racecadotril is an effective adjunctive therapy to oral rehydration. There is a clear effect of using certain probiotics, such as Lactobacillus GG or S. boulardii.
B. Uehleke, M. Ortiz and R. Stange
Silicea Gastrointestinal Gel might be suitable for uses extending beyond treatment of acute gastrointestinal disorders caused by pathogens. Improvement of various gastrointestinal symptoms in the course of treatment was documented for all patient subgroups, especially in patients suffering from GERD and IBS. Diarrhea without cramps was the single symptom which showed the most significant improvements.
Fedorova O.V., Fedulova E.N., Tutina O.A., Shumilova O.
A high clinical efficiency of Enterosgel preparation has been determined and its positive effect on the intestinal mucosa condition, digestion and absorption processes, the composition of small and large intestine-related microflora. The immunomodulative effect has been identified as conditioned by the normalization of eubiosis and the decreased inflammation activity in the intestinal mucosa.
Fedorova O.V., Fedulova E.N., Tutina O.A., Korkotashvili L.V.
IBD in children is accompanied by the development of endogenous intoxication, manifestation of which is conditioned by the severity of the process and dependent on the nature of intestinal lesion.
Enterosorption is an effective and safe method of sorption detoxification in the combination treatment of IBD in children, since it reduces the toxic load on the detoxification system of the body and the risk of developing infectious and autoimmune complications.
Nagornaya N.V., Dubovaya А.V.
The article describes different types of intoxication, presents a method of intracorporeal detoxification, and includes a classification of gastrointestinal adsorbents (enterosorbents). It summarizes the experience that has been gained with the intestinal adsorbent Enterosgel in the combination therapy of children and adults suffering from allergic diseases, gastrointestinal disorders, burn disease, chronic pyelonephritis, and recurrent non-specific vaginitis.
Dolzhenko M.N., Šipulin V.P., Sokolova L.K.
Research in primary and secondary prevention of atherosclerosis has shown that statin therapy can significantly reduce total and cardiovascular mortality.6,8,9 A number of patients could not take statins for a long time because of parenchyma liver damage and hepatocellular necrosis. In the treatment with the other groups of products in these patients fail to achieve a reduction in levels cholesterol and low density lipoproteins (LDL) to target values.
THE STUDY DRUG SAFETY OF "ENTEROSGEL®, PASTA FOR INTAKE (SWEET)" ALLOWS TO RECOMMEND ITS SUBMISSION TO THE TO THE MINISTRY OF HEALTH OF THE RUSSIAN FEDERATION AS LOW-TOXICITY DRUG AS THE PROCEDURE FOR EXPANDING INDICATIONS AND CHANGES IN INSTRUCTION FOR USE.